A significant portion of current research and development efforts, higher federal healthcare funding, and a growing geriatric cancer incidence are some of the drivers propelling the global CINV existing and pipeline drugs market.Wilmington, Delaware, United States, July 18, 2023 (GLOBE NEWSWIRE) In 2021, the global CINV existing and pipeline drugs market was estimated to be worth US$ 1.9 billion. It is expected to increase at a 5.8% CAGR from 2022 to 2031. The global market for CINV existing
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment Dominated by Roche texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Key role of pharma companies to fill gaps in terms of launch of precise drugs, NATP status for specific drugs, and meet unfulfilled clinical requirements to stir global market for anticoagulant